Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study

NCT00768859 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT00768859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00768859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2008
Completion date
May 31, 2012
Enrollment
111 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2 positive